Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)
Prediction of Severity of Liver Disease in Patients With Suspected Nonalcoholic Fatty Liver Disease (NAFLD) by 13C Octanoate Breath Test (OBT)
Sponsor: Meridian Bioscience, Inc.
Terminated
Budgetary Issues
A PHASE2 clinical study on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease, this trial is terminated or withdrawn. The trial is conducted by Meridian Bioscience, Inc. and has accumulated 9 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Meridian Bioscience, Inc.
- Virginia Commonwealth University
For direct contact, visit the study record on ClinicalTrials.gov .